Spots Global Cancer Trial Database for cervical
Every month we try and update this database with for cervical cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases | NCT06173401 | Spinal Metastas... | Single-fraction... Multi-fraction ... | 18 Years - | Stanford University | |
| Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases | NCT06173401 | Spinal Metastas... | Single-fraction... Multi-fraction ... | 18 Years - | Stanford University | |
| Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening | NCT04746872 | Human Papilloma... | Alinity m HR HP... | 25 Years - | Abbott Molecular | |
| Overlooked Population at Risk for AIN. | NCT01953094 | High Grade Cerv... Cervical Cancer | Screening Anal ... Screening Anal ... | 40 Years - | Sunnybrook Health Sciences Centre | |
| RT201(Tumor Antigen-specific Macrophage Tumor Vaccine) | NCT05930301 | Cervical | 18 Years - 75 Years | Wuxi People's Hospital | ||
| RT201(Tumor Antigen-specific Macrophage Tumor Vaccine) | NCT05930301 | Cervical | 18 Years - 75 Years | Wuxi People's Hospital | ||
| Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer | NCT01851772 | Cervical Cancer | Treatment with ... | - | Xoft, Inc. | |
| Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers | NCT00319748 | Breast Cancer Ovarian Cancer Endometrial Can... Cervical Cancer | 852A | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Immune Therapy of HPV-induced Cancers | NCT01462838 | HPV-induced Can... | P16_37-63 | 18 Years - | Oryx GmbH & Co. KG | |
| Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04892043 | Adult Solid Tum... | SQZ-AAC-HPV Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
| Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors | NCT00972205 | Cervical Ovarian Lung Breast Renal | paclitaxel CBT-1(Registere... Tc 99m sestamib... | 18 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| RT201(Tumor Antigen-specific Macrophage Tumor Vaccine) | NCT05930301 | Cervical | 18 Years - 75 Years | Wuxi People's Hospital | ||
| Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer | NCT01851772 | Cervical Cancer | Treatment with ... | - | Xoft, Inc. | |
| Laparoscopic Approach to Cervical Cancer | NCT00614211 | Cervical Cancer | Total Abdominal... Total Laparosco... | 18 Years - | Queensland Centre for Gynaecological Cancer | |
| Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV | NCT02403505 | HPV Infection | 9vHPV Vaccine p... | 24 Years - 64 Years | Medicine Invention Design, Inc | |
| Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04892043 | Adult Solid Tum... | SQZ-AAC-HPV Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
| Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04084951 | Adult Solid Tum... | SQZ-PBMC-HPV Atezolizumab Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
| GSK1120212+GSK2141795 for Cervical Cancer | NCT01958112 | Cervical Cancer | GSK1120212 (tra... GSK2141795 | 18 Years - | Dana-Farber Cancer Institute | |
| A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas | NCT01588678 | Advanced Solid ... Lymphoma | DS-3078a | 18 Years - | Daiichi Sankyo | |
| BKM120 for Patients With PI3K-activated Tumors | NCT01833169 | PI3K Pathway Ac... | BKM120 | 18 Years - 100 Years | Novartis | |
| A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study | NCT01271959 | Solid Organ Tum... | 18 Years - | Precision Therapeutics | ||
| Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma | NCT01554410 | Cervical Carcin... | Intensity Modul... Cisplatin Gemcitabine | 18 Years - | University of California, San Diego | |
| MaxAn Post Market Surveillance Validation | NCT01343693 | DDD Deformity Tumor Fracture | 18 Years - | Zimmer Biomet | ||
| Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases | NCT06173401 | Spinal Metastas... | Single-fraction... Multi-fraction ... | 18 Years - | Stanford University | |
| Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers | NCT00319748 | Breast Cancer Ovarian Cancer Endometrial Can... Cervical Cancer | 852A | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
| Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer | NCT00298064 | Cervical Cancer Cervix | Tissue Reposito... | - | University of New Mexico | |
| Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening | NCT04746872 | Human Papilloma... | Alinity m HR HP... | 25 Years - | Abbott Molecular | |
| Immune Therapy of HPV-induced Cancers | NCT01462838 | HPV-induced Can... | P16_37-63 | 18 Years - | Oryx GmbH & Co. KG | |
| Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening | NCT04746872 | Human Papilloma... | Alinity m HR HP... | 25 Years - | Abbott Molecular | |
| Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | NCT01953926 | Solid Tumors Ha... | Neratinib Fulvestrant Trastuzumab Paclitaxel | 18 Years - | Puma Biotechnology, Inc. | |
| Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT05357898 | Adult Solid Tum... | SQZ-eAPC-HPV Pembrolizumab | 18 Years - | SQZ Biotechnologies | |
| Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer | NCT01851772 | Cervical Cancer | Treatment with ... | - | Xoft, Inc. | |
| Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer | NCT01554397 | Cervical Cancer | Intensity Modul... Cisplatin | 18 Years - | University of California, San Diego |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
